Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230005/S005

Motiva SmoothSilk Round and Round Ergonomix Silicone Gel-Filled Breast Implants

Motiva USA, LLC · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONP230005/S005

What did the FDA approve?

The FDA record for P230005/S005 is a 30-day notice review track supplement classified as a process change covering manufacturer, sterilizer, packager or supplier. For Motiva SmoothSilk Round and Round Ergonomix silicone gel-filled breast implants, the stated purpose is adding an additional supplier for the shell patch and patch filler components. The decision field is listed as APPR, dated 2026-09-25, under product code FTR, specialty general and plastic surgery, applicant Motiva USA, LLC.

Because the identifier ties S005 to PMA P230005, this is a supplement to that original approval rather than an approval of the whole implant system. The record does not specify which supplier was added, the composition of the shell patch or patch filler, or any test data. The reported purpose of the submission is a stated change, not independent evidence of safety or clinical effectiveness, and no clinical conclusions follow.

Specific details absent from the supplied fields include supplier identity and any supporting manufacturing or performance information.

FDA approval order statement

adding an additional supplier for the shell patch and patch filler components
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Sep 25, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230005/S005
Regulatory pathway
PMA supplement
Product code
FTR
Decision code
APPR
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, breast, noninflatable, internal, silicone gel-filled.

Product code
FTR
FDA device class
3

For the original device and its historical approval scope, see PMA P230005. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230005 · Original PMA

    Motiva SmoothSilk Round Ergonomix Silicone Gel-Filled Breast Implants, Motiva SmoothSilk Round Silicone Gel-Filled Breas

  2. P230005/S005 received

    Application receipt date recorded by FDA.

  3. P230005/S005 · FDA decision

    135 Review Track For 30-Day Notice

  4. P230005/S002 · Related supplement

    Motiva SmoothSilk Round Ergonomix Silicone Gel-Filled Breast Implants, Motiva SmoothSilk Round Silicone Gel-Filled Breas

Timeline entries are records held by MedtechLedger for P230005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230005

Explore the linked device profile

Other records with product code FTR

Product / regulatory recordCompanyPathwayDecision dateSource
Tiger Aesthetics Medical, LLCPMA supplementNov 4, 2026FDA
Mentor Corp.PMA supplementOct 23, 2026FDA
Mentor Worldwide, LLCPMA supplementOct 23, 2026FDA
AllerganPMA supplementSep 29, 2026FDA
Mentor Worldwide, LLCPMA approvalJun 14, 2013FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Motiva USA, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2543 Mesa School Ln., Santa Barbara, CA, 93109

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records